Kymera Therapeutics, Inc. (KYMR)
121.05
+1.25
(+1.04%)
USD |
NASDAQ |
Aug 24, 16:00
121.01
-0.04
(-0.03%)
After-Hours: 20:00
Kymera Therapeutics Debt to Equity Ratio : 0.0521 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0521 |
| March 31, 2026 | 0.0523 |
| December 31, 2025 | 0.0521 |
| September 30, 2025 | 0.0888 |
| June 30, 2025 | 0.0882 |
| March 31, 2025 | 0.1098 |
| December 31, 2024 | 0.105 |
| September 30, 2024 | 0.0988 |
| June 30, 2024 | 0.1287 |
| March 31, 2024 | 0.1224 |
| December 31, 2023 | 0.2144 |
| September 30, 2023 | 0.2044 |
| June 30, 2023 | 0.1724 |
| March 31, 2023 | 0.1488 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0354 |
| September 30, 2022 | 0.0326 |
| June 30, 2022 | 0.0435 |
| March 31, 2022 | 0.0408 |
| December 31, 2021 | 0.0391 |
| September 30, 2021 | 0.0382 |
| June 30, 2021 | 0.0709 |
| March 31, 2021 | 0.0635 |
| December 31, 2020 | 0.0634 |
| September 30, 2020 | 0.0628 |
| June 30, 2020 | 0.1836 |
| March 31, 2020 | |
| December 31, 2019 | 0.6112 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.645B |
| Total Liabilities (Quarterly) | 136.19M |
| Shareholders Equity (Quarterly) | 1.509B |
| Current Ratio | 10.34 |
| Net Debt Paydown Yield | 0.02% |